简介内容：LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), can be used for the prevention and treatment of breast cancer.
Customer Service
